Enimmune corporation

Enimmune Corporation researches, develops, and sells drugs in Taiwan. Its offerings include EnVAX-A71, AimFlu-S(QIS), a tetanus vaccine adsorbed suspension for injection, a COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, along with biotechnology services. The company also develops vaccines for infectious diseases such as pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome. Its pipeline includes a cell culture-derived Japanese encephalitis vaccine in pre-clinical stage, an EV71+CA16 bivalent vaccine in research stage for hand-foot-mouth disease, and an Anti-RBD monoclonal antibody recognizing the receptor binding domain of the SARS-CoV-2 spike protein. Founded in 2014 and based in Taipei, Taiwan, Enimmune Corporation is a subsidiary of Adimmune Corporation.